Table 4 Patient background by LDA and REM groups

Age, years

65.1 ± 15.9

65.8 ± 13.2

Female, %

86.3

76.8

Disease duration, months

119.2 ± 122.2

83.4 ± 76.9

Stage (I/II/III/IV), %

43.2/28.4/13.7/14.7

48.5/33.3/11.1/7.1

TJC, 0–28

1.5 ± 1.4

0.3 ± 0.6

SJC, 0–28

0.5 ± 0.7

0.1 ± 0.3

CRP, mg/dL

0.3 ± 0.9

0.2 ± 0.3

ESR, mm/h

21.0 ± 21.7

15.9 ± 11.3

RF, IU/mL

99.0 ± 207.2

86.2 ± 128.2

RF positive, %

65.3

54.0

CCP, U/mL

229.8 ± 316.2

189.0 ± 297.5

CCP positive, %

70.6

62.4

MMP-3, ng/mL

88.1 ± 86.7

70.5 ± 75.0

SDAI

6.8 ± 2.0

1.3 ± 1.0

MTX use, %

78.9

60.6

MTX, mg/w

8.0 (3.0, 10.0)

6.0 (0.0, 8.0)

PSL use, %

8.4

15.2

PSL, mg/d

0.0 (0.0, 0.0)

0.0 (0.0, 0.0)

b(ts)DMARD use, %

44.2

40.4

HAQ-DI

0.8 ± 0.7

0.3 ± 0.6

EQ-5D-5L

0.8 ± 0.2

0.9 ± 0.2

MS, min

74.1 ± 260.2

19.5 ± 145.6

Pain VAS score, 0–100, mm

28.0 ± 18.7

4.5 ± 6.7

Fatigue VAS score, 0–100, mm

33.1 ± 23.2

4.9 ± 7.3

EGA, 0–100, mm

10.9 ± 7.4

2.0 ± 3.2

GS sum

2.5 ± 3.5

1.2 ± 2.0

GS score ≥ 1, %

69.5

44.4

GS score ≥ 2, %

31.6

16.2

GS score ≥ 3, %

11.6

5.1

PD sum

1.0 ± 2.1

0.3 ± 1.1

PD score ≥ 1, %

33.7

12.1

PD score ≥ 2, %

17.9

9.1

PD score ≥ 3, %

3.2

2.0